PFAS linkage
- PFAS compounds circulate through blood and can be excreted through urine, making urinary-tract health relevant to exposure review.
- Some research has examined PFAS exposure in relation to bladder cancer and other urinary outcomes, though evidence is less settled than for kidney and testicular cancer.
- Case review considers smoking history, occupational exposures, water contamination, and tumor grade or stage.
Bladder cancer symptoms
- Blood in the urine, often without pain
- Frequent urination, urgency, or burning with urination
- Pelvic, back, or flank pain
- Difficulty urinating or weak stream
- Fatigue, weight loss, or bone pain in advanced disease
Diagnosis and medical records
- Urinalysis, urine cytology, and evaluation for blood in urine
- Cystoscopy to inspect the bladder lining
- Transurethral resection of bladder tumor with pathology review
- CT urogram, MRI, or staging scans for higher-risk or invasive disease
Treatment options
- Transurethral tumor resection for diagnosis and treatment of non-muscle-invasive disease
- Intravesical therapy such as BCG or chemotherapy for selected cases
- Radical cystectomy, chemotherapy, radiation, immunotherapy, or targeted therapy for invasive or advanced disease
- Surveillance cystoscopy because recurrence is common
What patients should gather for intake
- Keep cystoscopy reports, pathology results, operative notes, staging scans, and treatment summaries.
- Include smoking history and any dye, rubber, metal, industrial, or firefighting exposures.
- Document contaminated drinking-water sources and years of exposure.
Medical and attorney advertising notice. This page is for general information only and is not medical advice. Talk with your treating clinician about diagnosis and treatment. Submitting an intake form does not create an attorney-client relationship, and cases may be referred to qualified national PFAS co-counsel.